The tablets, used in the treatment of chronic idiopathic constipation (CIC) in adults, are available in 1 mg and 2 mg strengths and are bioequivalent to Motegrity tablets of Takeda Pharmaceuticals U.S.A., Inc.
According to IQVIA MAT data for April 2025, the estimated annual market size for Prucalopride tablets in the US stands at $184 million.
The drug will be manufactured at Lupin’s Goa facility, the company said in a stock exchange filing.
Also Read: Glenmark Pharma’s Monroe facility in North America gets five USFDA observations
For the quarter ended March 31, 2025, Lupin reported a 12.2% year-on-year increase in revenue at ₹5,567.1 crore. EBITDA rose 22.5% to ₹996.85 crore, while net profit more than doubled to ₹794.86 crore, beating CNBC-TV18 estimates.
Shares of Lupin Ltd were trading 0.94% lower at ₹1,917.10 on the NSE at 2:49 PM.
(Edited by : Sheersh Kapoor)
